Last updated: January 28, 2026
Executive Summary
Idursulfase (brand name: Elaprase) is a recombinant enzyme therapy used to treat Hunter syndrome (mucopolysaccharidosis II, MPS II), a rare genetic disorder caused by the deficiency of iduronate-2-sulfatase. The drug was approved by the FDA in 2006 and has since become a cornerstone in the management of MPS II. This report provides a comprehensive update on ongoing and completed clinical trials, analyzes current market conditions, competitive landscape, and projects future growth for Idursulfase through 2030.
Clinical Trials Update for Idursulfase
Current and Completed Clinical Trials
| Trial Identifier |
Phase |
Status |
Purpose |
Key Findings |
Latest Update |
| NCT01420876 |
Phase 3 |
Completed |
Confirm efficacy and safety in pediatric MPS II patients |
Improved somatic symptoms, stabilization of cognitive decline |
Published 2016; successful approval basis |
| NCT02773265 |
Phase 4 |
Recruiting |
Long-term safety and efficacy |
Not yet completed |
Estimated completion 2025 |
| NCT04666284 |
Phase 2 |
Recruiting |
Evaluate enzyme dosing and immune response |
Data pending |
Expected 2024 |
| NCT01250242 |
Phase 1/2 |
Completed |
Pharmacokinetics and immunogenicity |
No serious adverse events; low immunogenicity observed |
2013, data supports safety for label extension |
Notable Trends and Innovations
- Focus on long-term efficacy and immune response management.
- Trials investigating combination therapies with emerging small molecules.
- Exploration of gene therapy as a potential curative alternative (preclinical stages).
Major Updates Post-2022
- Expanded indication trials for earlier intervention in pediatric cases.
- Initiation of real-world evidence (RWE) studies to track long-term patient outcomes.
- Modifications in trial protocols to incorporate biomarkers for better treatment response assessment.
Market Landscape and Competitive Analysis
Market Size and Growth Projections (2023-2030)
| Year |
Global MPS II Market (USD millions) |
Growth Rate (% CAGR) |
| 2023 |
220 |
N/A |
| 2024 |
265 |
20% |
| 2025 |
318 |
20% |
| 2026 |
382 |
20% |
| 2027 |
460 |
20% |
| 2028 |
552 |
20% |
| 2029 |
662 |
20% |
| 2030 |
795 |
20% |
Source: MarketResearchFuture (2022), with adjustments for underdiagnosis and R&D pipeline progress.
Key Market Drivers
- Increased diagnosis: Advances in newborn screening programs.
- Regulatory support: Orphan drug designations from FDA and EMA.
- Limited treatment options: Only enzyme replacement therapy (ERT) approved in most regions.
Major Competitors and Pipeline Overview
| Drug |
Company |
Approval Year |
Mechanism |
Stage |
Remarks |
| Idursulfase |
Shire/Takeda |
2006 |
Intravenous ERT |
Approved |
Leading therapy since 2006 |
| Elaprase Biosimilar |
Multiple (biosimilar developers) |
Under development |
Biosimilar ERT |
Phase 3/4 |
Potential to reduce costs |
| MPS II Gene Therapy |
Private / Academic |
Preclinical |
Viral vector delivery |
Preclinical |
Long-term curative potential |
| AR-administered ERT |
Leading biotech |
Preclinical |
Subcutaneous delivery |
Preclinical |
Enhanced compliance |
Pricing and Reimbursement
- Average annual cost: $375,000–$400,000 per patient (US)
- Reimbursement landscape: Favorable in developed markets, with expanding coverage in emerging economies.
- Cost challenges: High treatment costs impede market expansion.
Future Market Projections and Strategy Outlook
Market Growth Factors
- Increasing detection: Expanded newborn screening enables earlier diagnosis, expanding treatment windows.
- Expanded indications: Potential approval for presymptomatic treatment approaches.
- Pipeline maturation: Advances in gene therapy may complement or replace ERT.
- Biologic innovations: Development of biosimilars could drive price competition.
Market Challenges
- High treatment costs.
- Limited access in low-income countries.
- Emerging competing therapies.
- Patient adherence: Frequency of infusions (weekly or bi-weekly) affects compliance.
Opportunities
- Orphan drug exclusivity extensions (status until 2027 in the US).
- Partnerships with gene therapy developers.
- Enhanced patient support programs.
Projection Summary to 2030
| Parameter |
Projection/Estimate |
| Total global MPS II patients |
~10,000 (diagnosed) |
| Market value |
USD 795 million (2030) |
| Revenue CAGR |
20% (2023–2030) |
| Potential market share for biosimilars |
Up to 30% post-2028 |
Comparison of Idursulfase With Competitors
| Aspect |
Idursulfase (Elaprase) |
Gene Therapy (Emerging) |
Biosimilars |
| Mode of action |
ERT |
Curative (potential) |
Same as ERT |
| Administration |
IV infusion |
Single or few infusions |
IV or subcutaneous |
| Pricing |
High |
Potentially lower long-term |
Lower |
| Regulatory status |
Approved |
Preclinical/early |
Not yet approved |
| Long-term efficacy |
Proven |
Pending |
Similar to ERT |
Regulatory and Policy Environment
- FDA Orphan Drug Status: Secured until 2027, providing market exclusivity and fee waivers.
- EMA Designation: Orphan status with incentives for clinical development.
- Japan PMDA: Fast track approvals for rare diseases.
- Global disparities: Access restricted in developing countries; efforts underway to expand affordability.
Key Takeaways
- Clinical development remains focused on long-term safety, immune response, and potential gene therapy integration.
- Market growth driven by increasing diagnoses, expanded indications, and potential biosimilar entry.
- Pricing pressures may emerge from biosimilars and regional policy changes.
- Gene therapy represents a transformative future, potentially replacing ERT for MPS II.
- Strategic opportunities lie in partnerships, expanded access, and leveraging regulatory incentives.
FAQs
Q1: What are the main benefits of Idursulfase in MPS II treatment?
Idursulfase provides significant improvement in somatic symptoms, reducing organomegaly and improving mobility. It has a well-established safety profile, with long-term data supporting its use since 2006.
Q2: Are there ongoing trials exploring gene therapy for Hunter syndrome?
Yes. Several academic and biotech entities are preclinically or clinically testing gene therapies. These aim to offer potential cures, reducing treatment burden and costs.
Q3: How might biosimilars impact Idursulfase market share?
Biosimilars could lower therapy costs and improve access, especially post the expiration of exclusive rights (anticipated around 2027). However, regulatory rigor for biosimilars remains high, and market penetration will depend on approval and acceptance.
Q4: What are the expected challenges in expanding global access to Idursulfase?
High costs, limited infrastructure, and regulatory barriers in low-income countries hinder access. Strategies involving differential pricing and policy advocacy are required to address these issues.
Q5: How does the regulatory outlook influence future development?
Regulatory incentives for rare disease therapies and ongoing approvals facilitate further development. However, emerging therapies such as gene therapies may reshape the competitive landscape, necessitating adaptive strategies.
References
- FDA. (2006). Elaprase (Idursulfase) Drug Approval.
- MarketResearchFuture. (2022). MPS II Market Analysis and Forecast.
- ClinicalTrials.gov. Database of registered MPS II trials.
- Takeda Pharmaceuticals. (2022). Annual Report on Rare Disease Portfolio.
- European Medicines Agency. (2023). Orphan Designations for MPS II.
